ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients - Archive ouverte HAL Access content directly
Journal Articles Annals of Oncology Year : 2017

ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients

(1) , (2) , (1) , , , , (1) , , (1) , , , , , , , (3) , , , , , , (1) , (1) , (4)
1
2
3
4
C. Menetrier-Caux
  • Function : Author
Isabelle Ray-Coquard
G. Garin
  • Function : Author
C. Cropet
  • Function : Author
E. Verronese
  • Function : Author
Thomas Bachelot
P. Rebattu
  • Function : Author
Pierre Cassier
  • Function : Author
Sylvie Chabaud
  • Function : Author
T. Croughs
  • Function : Author
Pierre Dupont
  • Function : Author
C. Cadore
  • Function : Author
G. Clapisson
  • Function : Author
C. Bardin-Dit-Courageot
  • Function : Author
C. Rigal
  • Function : Author
A. N'Kodia
  • Function : Author
L. Gilles-Afchain
  • Function : Author
M. Morre
  • Function : Author

Keywords

Dates and versions

hal-01795705 , version 1 (18-05-2018)

Identifiers

Cite

O. Tredan, C. Menetrier-Caux, Isabelle Ray-Coquard, G. Garin, C. Cropet, et al.. ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients. Annals of Oncology, 2017, ⟨10.1093/annonc/mdx058⟩. ⟨hal-01795705⟩
35 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More